ReviewFrontiers in oncology2025
The impact of heart irradiation dose on cardiac injury and survival in lung cancer patients after radiotherapy.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative analysis of artificial intelligence-based contouring of cardiac substructures on computed tomography scans for radiation therapy.Physics and imaging in radiation oncology · 2026Article
- Impact of Heart Dose on Survival in Palliative Radiotherapy for Bone Metastases: Propensity Score-matched Analysis.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic radiotherapy is a primary treatment modality for lung cancer, with approximately two-thirds of patients receiving it. The association between heart dose and post-radiotherapy survival and cardiac injury represents a critical area of contemporary radiotherapy research, yet understanding of radiation-induced heart disease (RIHD) in lung cancer remains incomplete. This review synthesizes literature on the effects of heart dose on survival and substructure-specific cardiac injury in lung cancer patients, evaluating thresholds for reversible and irreversible damage to cardiac substructures. We further summarize key mechanisms underlying RIHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.